絞り込み

16355

広告

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.

著者 Mitchell P
Curr Med Res Opin.2011 Jul ; 27(7):1465-75.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Ophthalmology, University of Sydney, Sydney, Australia. paul.mitchell@sydney.edu.au

スターを付ける スターを付ける     (856view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Medical

Miscellaneous

To systematically review ocular and systemic events in treatment of wet age-related macular degeneration (AMD) with anti-vascular endothelial growth factor antibodies, ranibizumab and bevacizumab, and to provide a detailed perspective of their differences on clinical use, efficacy and safety.
PMID: 21623685 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード